Viacyte

Quick reaction to milestone ViaCyte data on a diabetes patient

VC-01-post-implant-final1-e1503703572933, viacyte

ViaCyte released encouraging data just now on a patient with implanted stem cell-derived pancreas-like device whose diabetes improved. You can read more about this in the Endpoints piece that I linked to in the previous sentence. Stem cells for diabetes; the ViaCyte update The idea of stem cells for diabetes has been more on my …

Quick reaction to milestone ViaCyte data on a diabetes patient Read More »

Stem cell therapy for diabetes updates: expected IPO, CRISPR, new pubs, more

stem cell therapy for diabetes

The idea of stem cell therapy for diabetes is both exciting and in a way practical. By that I mean that there’s a good common sense foundation here. The idea of stem cell therapy for diabetes What do I mean? If medical researchers can replace lost beta cells in the pancreas using stem cell-produced beta …

Stem cell therapy for diabetes updates: expected IPO, CRISPR, new pubs, more Read More »

20/20 vision? The Niche’s 20 stem cell & regenerative medicine predictions for 2020

The-Niche-stem-cell-predictions-2020

Every year in December and early January I do a post predicting some key events for the stem cell and regenerative medicine field for the upcoming year and today’s post contains my predictions for 2020. You can see my past 2019 predictions along with my grades for them here. I gave myself a B+ for …

20/20 vision? The Niche’s 20 stem cell & regenerative medicine predictions for 2020 Read More »

B+ on my report card on my 20 stem cell predictions for 2019

stem-cell-crystal-ball-predictions-1

Last year around this time I took my annual plunge to make 20 predictions for the coming year for the stem cell and regenerative medicine field. I even made a crystal ball graphic to highlight the complexity of the stem cell ecosystem into which these predictions were embedded (see image) for 2019. How’d I do? …

B+ on my report card on my 20 stem cell predictions for 2019 Read More »

ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more

ViaCyte-CyT49-PSC

ViaCyte is one of the most exciting stem cell and regenerative medicine biotech companies so I like to try to check in with them regularly. Today’s post is my new interview with ViaCyte leader Paul Laikind on recent developments. We had a great chat about the science and how things are looking upbeat for the …

ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more Read More »

7-Year Glitch? Updates on my overly optimistic 2013 stem cell predictions for 2020

STEM-CELL-PREDICTIONS

Back in 2013, a half dozen years ago, I went out on a limb and made predictions for the stem cell field for 2020. These are different than my yearly predictions for the coming year (for instance, you can see my predictions made in 2018 for this year of 2019 here). As to my 2013 …

7-Year Glitch? Updates on my overly optimistic 2013 stem cell predictions for 2020 Read More »

Good final grades on my 20 x 2018 stem cell predictions

stem-cell-crystal-ball-300x3001

Each year I make a list of stem cell predictions for the following year and I’ll release my predictions for 2019 soon, but first I’m grading how my 20 predictions for 2018 turned out. It seems I did better than usual predicting what would happen this year. I only got a couple partial credit or …

Good final grades on my 20 x 2018 stem cell predictions Read More »

Quick Q&A with ViaCyte CEO on CRISPR-stem cell work

VC-01-post-implant-final1-e1503703572933, viacyte

We heard this week about the encouraging news of a new CRISPR-stem cell collaboration between stem cell biotech ViaCyte and CRISPR Therapeutics. The goal of the team is to make genetically engineered pancreatic derivatives from stem cells that would have a unique immune stealthiness. If such an approach was successful, patients would not need to …

Quick Q&A with ViaCyte CEO on CRISPR-stem cell work Read More »